Meeting
2019 Gastrointestinal Cancers Symposium
Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
Authors
Tanios S. Bekaii-Saab
Mayo Clinic, Phoenix, AZ
Tanios S. Bekaii-Saab , Juan W. Valle , Mitesh J. Borad , Davide Melisi , Arndt Vogel , Luis Féliz , Christine Francis Lihou , Huiling Zhen , Ghassan K. Abou-Alfa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03656536
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS462)
DOI
10.1200/JCO.2019.37.4_suppl.TPS462
Abstract #
TPS462
Poster Bd #
Q1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.
First Author: Ghassan K. Abou-Alfa
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
First Author: Milind M. Javle
Poster
2016 ASCO Annual Meeting
A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
First Author: Thomas Powles